
    
      1. Number and cumulative duration of Raynaud's attacks.

        2. Adverse events and changes in vital signs.

        3. SLx-2101 pharmacokinetic parameters derived after dosing on Day 1 and Day maximum plasma
           concentration (Cmax), area under the plasma concentration-time curve (AUC0-4), time to
           Cmax (tmax), and accumulation ratio
    
  